Condition Directory

Heart Failure clinical trials

Directory of U.S. ClinicalTrials.gov public records for Heart Failure. Browse Heart Failure recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 10, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

547

Shown on this page

Current sort

How Heart Failure studies are organized in the registry

Heart failure records routinely distinguish reduced versus preserved ejection fraction — the abbreviations HFrEF and HFpEF appear directly in titles and condition fields and are the cleanest way to split the portfolio. Device and monitoring studies form a substantial share alongside drug trials.

Terms that often appear in related listings

HFrEF HFpEF preserved ejection fraction cardiomyopathy

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 37–48 of 547 matching trials for Heart Failure.

Live ClinicalTrials.gov results.

Active filters: "cardiomyopathy" Clear condition filters

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Tricuspid Regurgitation, Tricuspid Valve Disease
Interventions: TricValve® Transcatheter Bicaval Valve System; Device
Lead sponsor: P+F Products + Features USA Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 36
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 31 more

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download, Medication intervention, Not Randomized to Device or Medication Intervention; Device · Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 826 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 53
States / cities: Mesa, Arizona • Jonesboro, Arkansas • Mission Viejo, California + 47 more

Conditions: Transthyretin Amyloid Cardiomyopathy
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Palo Alto, California • Jacksonville, Florida • Chicago, Illinois + 3 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: SGLT-2 inhibitor, SGLT2 inhibitor; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions: progressive resistance training, combined aerobic + resistance training; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 60 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions: COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting; Device · Other
Lead sponsor: Peerbridge Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Pasadena, California • Nashville, Tennessee

Conditions: Cardiac Sarcoidosis
Interventions: Rilonacept; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Baltimore, Maryland • Rochester, Minnesota

Conditions: Pulmonary Hypertension Associated With HFpEF
Interventions: TNX-103, Placebo; Drug
Lead sponsor: Tenax Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 46
States / cities: Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more

Conditions: Heart Failure, Cardiomyopathy
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Obstructive Hypertrophic Cardiomyopathy
Interventions: Mavacamten, Non-mavacamten symptomatic oHCM therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 60
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more

Conditions: ATTR Amyloidosis With Cardiomyopathy, Heart Failure
Interventions: ATTR-CM AI-ECG and AI-Echo Model; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

About this Heart Failure clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Heart Failure as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Heart Failure.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Heart Failure clinical trials

How Heart Failure studies are organized in the registry

Filter and sort this condition

Live official records

TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

PREACTIVE: Preconditioning Exercise Intervention to Improve Symptoms and Quality of Life in Comorbid Atrial Fibrillation and HFpEF

Incretin Therapies in Obesity-related HFpEF

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

Rilonacept in Subjects With Cardiac Sarcoidosis

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Impella Reverse Remodeling in End-Stage Heart Failure

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

About this Heart Failure clinical trials directory page